Regeneron (REGN)

295.87 +9.72 (3.40%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (11/6/19 *Est.)

Latest Headlines

Regeneron (REGN), Sanofi (SNY) Report Publication of Results from Two Positive Phase 3 Trials of Dupixent (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps September 20, 2019 7:01 AM - StreetInsider The Lancet Publishes Results from Two Positive Phase 3 Trials of Dupixent® (dupilumab) in Severe Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) September 20, 2019 6:59 AM - PR NewsWire Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for severe chronic rhinosinusitis with nasal polyposis   September 20, 2019 6:49 AM - StreetInsider Regeneron (REGN) Announces CHMP Recommended Approval of Dupixent for Severe Chronic Rhinosinusitis with Nasal Polyposis September 20, 2019 6:44 AM - StreetInsider CHMP Recommends Approval of Dupixent® (dupilumab) for Severe Chronic Rhinosinusitis with Nasal Polyposis September 20, 2019 6:44 AM - PR NewsWire Educational Campaign Helps Teens and Their Caregivers Tackle Everyday Challenges of Living with Moderate-to-severe Atopic Dermatitis September 18, 2019 6:59 AM - PR NewsWire Regeneron Debuts on Prestigious Dow Jones Sustainability World Index of Most Sustainable Companies September 17, 2019 7:00 AM - PR NewsWire Form 4 REGENERON PHARMACEUTICAL For: Sep 10 Filed by: Sanofi September 12, 2019 5:01 PM - SEC Filing U.S. District Court Invalidates Amgen Patent Claims Targeting PCSK9 August 28, 2019 4:56 PM - PR NewsWire Sanofi : U.S. District Court invalidates Amgen patent claims targeting PCSK9 August 28, 2019 4:36 PM - StreetInsider Amgen (AMGN) patent on blockbuster Repatha drug invalid, judge rules - Bloomberg (REGN) August 28, 2019 3:05 PM - StreetInsider Regeneron Announces Upcoming Investor Conference Presentation August 15, 2019 9:30 AM - PR NewsWire Regeneron (REGN) Reports Positive Topline Results from Phase 3 Trial of Evinacumab August 14, 2019 7:02 AM - StreetInsider Regeneron Announces Positive Topline Results from Phase 3 Trial of Evinacumab in Patients with Severe, Inherited Form of High Cholesterol August 14, 2019 7:00 AM - PR NewsWire Regeneron (REGN) Announces FDA Approval for EYLEA Injection Prefilled Syringe August 13, 2019 7:04 AM - StreetInsider FDA Approves EYLEA® (aflibercept) Injection Prefilled Syringe August 13, 2019 7:00 AM - PR NewsWire Regeneron (REGN) PALM Ebola Clinical Trial Stopped Early for Superiority August 12, 2019 10:03 AM - StreetInsider PALM Ebola Clinical Trial Stopped Early as Regeneron's REGN-EB3 Therapy Shows Superiority to ZMapp in Preventing Ebola Deaths August 12, 2019 10:01 AM - PR NewsWire Regeneron Pharma (REGN) PT Lowered to $447 at SVB Leerink August 7, 2019 9:06 AM - StreetInsider Regeneron Pharma (REGN) PT Lowered to $344 at BMO Capital August 7, 2019 8:14 AM - StreetInsider Regeneron Pharma (REGN) PT Raised to $399 at RBC Capital August 7, 2019 7:22 AM - StreetInsider Baird Upgrades Regeneron Pharma (REGN) to Outperform August 7, 2019 4:28 AM - StreetInsider Form 10-Q REGENERON PHARMACEUTICAL For: Jun 30 August 6, 2019 7:56 AM - SEC Filing Form 8-K REGENERON PHARMACEUTICAL For: Aug 06 August 6, 2019 7:36 AM - SEC Filing Regeneron (REGN) Tops Q2 EPS by 61c, Revenues Beat August 6, 2019 6:43 AM - StreetInsider Regeneron Reports Second Quarter 2019 Financial and Operating Results August 6, 2019 6:30 AM - PR NewsWire Regeneron (REGN) Reports Dupixent Granted European Commission Approval for Adolescents with Moderate-to-Severe Atopic Sermatitis August 6, 2019 5:57 AM - StreetInsider Regeneron (REGN) Highlights Positive Topline Results in Phase 3 Trial August 6, 2019 5:48 AM - StreetInsider Sanofi : Dupixent® (dupilumab) showed positive topline results in Phase 3 trial of children aged 6 to 11 years with severe atopic dermatitis August 6, 2019 1:06 AM - StreetInsider Dupixent® (dupilumab) Showed Positive Topline Results in Phase 3 Trial of Children Aged 6 to 11 Years with Severe Atopic Dermatitis August 6, 2019 1:04 AM - PR NewsWire Sanofi : Dupixent® (dupilumab) approved by European Commission for adolescents with moderate-to-severe atopic dermatitis August 6, 2019 1:01 AM - StreetInsider Dupixent® (dupilumab) Approved by European Commission for Adolescents with Moderate-to-Severe Atopic Dermatitis August 6, 2019 12:59 AM - PR NewsWire Regeneron Pharma (REGN) and Amgen (AMGN) Could Rally on Recently Introduced Legislation - Piper Jaffray July 24, 2019 9:20 AM - StreetInsider Regeneron (REGN) Trades at High, Up 4.6% July 23, 2019 2:49 PM - StreetInsider Regeneron Announces the 2019 Winners of the Regeneron Prize for Creative Innovation July 18, 2019 7:30 AM - PR NewsWire Regeneron Pharma (REGN) PT Lowered to $375 at Morgan Stanley July 15, 2019 8:59 AM - StreetInsider German Court Ruling Positive for Amgen (AMGN), Negative for Regeneron (REGN) - Cowen July 12, 2019 8:58 AM - StreetInsider Regeneron (REGN) Hits Low, Down 5% July 10, 2019 11:04 AM - StreetInsider Regeneron to Report Second Quarter 2019 Financial and Operating Results and Host Conference Call and Webcast on August 6, 2019 July 8, 2019 9:30 AM - PR NewsWire Sanofi (SNY) announces Libtayo approved for advanced cutaneous squamous cell carcinoma in European Union July 1, 2019 10:02 AM - StreetInsider Sanofi : Libtayo® (cemiplimab) approved for advanced cutaneous squamous cell carcinoma in the European Union July 1, 2019 10:01 AM - StreetInsider Libtayo® (cemiplimab) Approved for Advanced Cutaneous Squamous Cell Carcinoma in the European Union July 1, 2019 10:00 AM - PR NewsWire Sanofi : CHMP recommends approval of Dupixent® (dupilumab) for moderate-to-severe atopic dermatitis in adolescents June 28, 2019 7:01 AM - StreetInsider Regeneron Pharmaceuticals, Inc. (REGN), Sanofi (SNY) Report CHMP Approval of Dupixent (dupilumab) for Moderate-to-Severe Atopic Dermatitis in Adolescents June 28, 2019 6:59 AM - PR NewsWire Sanofi : FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis June 26, 2019 1:31 PM - StreetInsider Regeneron (REGN), Sanofi Announce FDA Approval of Dupixent for Chronic Rhinosinusitis with Nasal Polyposis June 26, 2019 1:30 PM - StreetInsider FDA approves Dupixent® (dupilumab) for chronic rhinosinusitis with nasal polyposis June 26, 2019 1:30 PM - PR NewsWire FDA Approves Dupixent® (dupilumab) for Chronic Rhinosinusitis with Nasal Polyposis June 26, 2019 1:29 PM - PR NewsWire Full Article List